HanAll Biopharma's shares surged by over 26% during trading after the company confirmed the efficacy of its drug candidate for patients with refractory rheumatoid arthritis.
According to the Korea Exchange, as of 1:52 PM on November 10, HanAll Biopharma's stock was trading at 47,050 won, up 9,950 won (26.82%) from the previous trading day.
On the same day, HanAll Biopharma announced that its global partner, Immunovant, met the primary endpoint in a clinical trial of imeroprate (IMVT-1402) for patients with refractory rheumatoid arthritis (D2T RA). Imeroprate is a drug candidate that HanAll Biopharma licensed to Immunovant.
The trial targeted patients who had not experienced symptom improvement despite using two or more different targeted therapies. In the Phase 2 segment, the ACR20 response rate at week 28 for the high-dose (600 mg) imeroprate group was 92.5%, significantly higher than the placebo group (75.6%).
Exploratory endpoints ACR50 and ACR70 response rates also showed promising results in the high-dose group, recording 80% and 52.5%, respectively. No serious adverse events or treatment discontinuations due to adverse reactions were reported.
Immunovant plans to discuss further development plans with the U.S. Food and Drug Administration (FDA) later this year. Clinical results for imeroprate related to Graves' disease and myasthenia gravis are expected to be announced next year.
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.